Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT

被引：0

作者：

Baron, Ari David

Lopez, Carlos Lopez

Chang, Stephen Lam

Piscaglia, Fabio

Ramji, Zahra

Ren, Min

Estenson, Kasey

Vogel, Arndt

Gholam, Pierre

机构：

[1] Marques Valdecilla Univ Hosp, IDIVAL, Santander, Spain

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] IRCCS Azienda Ospedaliero Univ Bologna, Bologna, Italy

[4] Eisai Inc, Nutley, NJ USA

[5] Hannover Med Sch, Hannover, Germany

[6] Case Western Reserve Univ Sch Med, Cleveland, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4078

引用

页数：1

共 50 条

[1] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Cheng, A. -L.
Finn, R. S.
Qin, S.
Han, K. -H.
Ikeda, K.
Piscaglia, F.
Baron, A.
Park, J. -W.
Han, G.
Jassem, J.
Blanc, J. F.
Vogel, A.
Komov, D.
Evans, T. J.
Lopez, C.
Dutcus, C.
Ren, M.
Kraljevic, S.
Tamai, T.
Kudo, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211
[2] Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)
Cheng, Ann-Lii
Finn, Richard S.
Qin, Shukui
Han, Kwan-Hyub
Ikeda, Kenji
Piscaglia, Fabio
Baron, Ari
Park, Joong-Won
Han, Guohong
Jassem, Jacek
Blanc, Jean Frederic
Vogel, Arndt
Komov, Dmitry
Evans, T. R. Jeffry
Lopez, Carlos
Dutcus, Corina
MinRen
Kraljevic, Silvija
Tamai, Toshiyuki
Bower, John
Kudo, Masatoshi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 116 - 116
[3] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Cheng, Ann-Lii
Finn, Richard S.
Qin, Shukui
Han, Kwang-Hyub
Ikeda, Kenji
Piscaglia, Fabio
Baron, Ari David
Park, Joong-Won
Han, Guohong
Jassem, Jacek
Blanc, Jean -Frederic
Vogel, Arndt
Komov, Dmitry
Evans, T. R. Jeffry
-Lopez, Carlos Lopez
Dutcus, Corina E.
Ren, Min
Kraljevic, Silvija
Tamai, Toshiyuki
Kudo, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy
Evans, T. R. Jeffry
Kudo, Masatoshi
Cheng, Ann-Lii
Wyrwicz, Lucjan S.
Ngan, Roger Kc
Blanc, Jean-Frederic
Baron, Ari David
Vogel, Arndt
Ikeda, Masafumi
Piscaglia, Fabio
Qin, Shukui
Hoshi, Taisuke
Tamaki, Ryuji
Funahashi, Yasuhiro
Okpara, Chinyere E.
Sagane, Koji
Xing, Dongyuan
Minoshima, Yukinori
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
Finn, R. S.
Kudo, M.
Cheng, A-L.
Wyrwicz, L.
Ngan, R.
Blanc, J-F.
Baron, A. D.
Vogel, A.
Ikeda, M.
Piscaglia, F.
Han, K-H.
Qin, S.
Minoshima, Y.
Funahashi, Y.
Ren, M.
Dairiki, R.
Sachdev, P.
Tamai, T.
Dutcus, C.
Evans, T. R. J.
ANNALS OF ONCOLOGY, 2017, 28
[6] Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn, R. S.
Kudo, M.
Cheng, A-L.
Wyrwicz, L.
Ngan, R.
Blanc, J. F.
Baron, A. D.
Vogel, A.
Ikeda, M.
Piscaglia, F.
Han, K-H.
Qin, S.
Minoshima, Y.
Kanekiyo, M.
Ren, M.
Dairiki, R.
Tamai, T.
Dutcus, C. E.
Funahashi, Y.
Evans, T. R. J.
ANNALS OF ONCOLOGY, 2018, 29
[7] Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Lencioni, Riccardo
Kudo, Masatoshi
Finn, Richard S.
Qin, Shukui
Han, Kwang-Hyub
Ikeda, Kenji
Cheng, Ann-Lii
Piscaglia, Fabio
Han, Guohong
Ikeda, Masafumi
Simon, Krzysztof
Komov, Dmitry
OuYang, Xuenong
Evans, T. R. Jeffry
Sung, Max W.
Binder, Terri A.
Damon, Andrew
Kraljevic, Silvija
Ren, Min
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[8] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Yau, T.
Galle, P. R.
Decaens, T.
Sangro, B.
Qin, S.
Park, J-W.
Ikeda, M.
Tai, D. W. M.
Chiu, C-F.
Chon, H. J.
Kang, Y-K.
Hiraoka, A.
Huang, Y-H.
Lee, T-Y.
Numata, K.
Yamashita, T.
Ogata, T.
Hreiki, J.
Lu, Y.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1451
[9] Characterization of tumor response with lenvatinib (LEN) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Mahipal, A.
Cheng, A-L.
Kudo, M.
Burgoyne, A.
Kalyan, A.
Lencioni, R.
Lopez, C.
Pracht, M.
Daniele, B.
Palmer, D.
Baron, A.
Park, J-W.
Estenson, K.
Christou, V.
Ren, M.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S76 - S77
[10] Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC)
Alsina, Angel
Kudo, Masatoshi
Vogel, Arndt
Cheng, Ann-Lii
Tak, Won Young
Ryoo, Baek-Yeol
Evans, T. R. Jeffry
Lopez, Carlos Lopez
Daniele, Bruno
Blanc, Jean-Frederic
Ren, Min
Baldwin, Rae Lynn
Izumi, Namiki
Qin, Shukui
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →